These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 1820495

  • 21. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.
    Yates AJ, Murray RM, Jerums GJ, Martin TJ.
    Aust N Z J Med; 1987 Aug; 17(4):387-91. PubMed ID: 3435316
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
    Body JJ, Borkowski A, Cleeren A, Bijvoet OL.
    J Clin Oncol; 1986 Aug; 4(8):1177-83. PubMed ID: 3016205
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P, Thiébaud D, Perey L, von Fliedner V.
    Recent Results Cancer Res; 1989 Aug; 116():54-66. PubMed ID: 2762665
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Mithramycin treatment of intractable hypercalcemia due to parathyroid carcinoma.
    Singer FR, Neer RM, Murray TM, Keutmann HT, Deftos LJ, Potts JT.
    N Engl J Med; 1970 Sep 17; 283(12):634-6. PubMed ID: 5450637
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy.
    Adami S, Bolzicco GP, Rizzo A, Salvagno G, Bertoldo F, Rossini M, Suppi R, Lo Cascio V.
    Bone Miner; 1987 Aug 17; 2(5):395-404. PubMed ID: 2975514
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.
    Nussbaum SR, Warrell RP, Rude R, Glusman J, Bilezikian JP, Stewart AF, Stepanavage M, Sacco JF, Averbuch SD, Gertz BJ.
    J Clin Oncol; 1993 Aug 17; 11(8):1618-23. PubMed ID: 8336198
    [Abstract] [Full Text] [Related]

  • 36. [Disodium pamidronate (APD) in therapy of hypercalcemia in primary hyperparathyroidism].
    Kotzmann H, Svoboda T, Bernecker P, Clodi M, Woloszczuk W, Niederle B, Waldhäusl W, Luger A.
    Wien Klin Wochenschr; 1994 Aug 17; 106(13):422-5. PubMed ID: 8091766
    [Abstract] [Full Text] [Related]

  • 37. Neoplastic hypercalcemia: physiologic response to intravenous etidronate disodium.
    Jacobs TP, Gordon AC, Silverberg SJ, Shane E, Reich L, Clemens TL, Gundberg CM.
    Am J Med; 1987 Feb 23; 82(2A):42-50. PubMed ID: 3030098
    [Abstract] [Full Text] [Related]

  • 38. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
    Thiébaud D, Jacquet AF, Burckhardt P.
    Arch Intern Med; 1990 Oct 23; 150(10):2125-8. PubMed ID: 2222097
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.